A subsidiary of Danish pharmaceutical company Novo Nordisk is investing 1.5 billion Danish kroner (about $220 million) to build a new plant on an existing site in Köge, a small seaside town about 25 miles southwest of Copenhagen.
The approximately 8,000 square metre facility will support pharmaceutical production and storage as well as include office and laboratory space and will be built on land purchased by Novo’s PharmaTech division in March 2023.
“This is the largest investment in Novo Nordisk Pharmatec’s 75-year history,” said Ulla Grove Krogsgaard Thomsen, head of the unit. August 16th Statement“We are in a period of growth and, in line with our growth strategy, we are expanding our production to ensure a more secure and reliable supply of products.”
Specifically, the facility will produce ingredients for Novo’s chronic disease drugs, including those for diabetes and obesity. The company is investing billions of dollars in expanding its manufacturing footprint as demand for drugs such as Ozempic and Wegovi outstrips supply. Recently, Novo $4.1 billion to build new factory North Carolina.
Novo is investing heavily in manufacturing to keep pace with rival Eli Lilly, which is also Production expansion We will sell the obesity and diabetes drugs Zepbound and Maunjaro as soon as possible.
The Köge expansion will be relatively small and will create around 50 new jobs. Novo Nordisk Pharmatec said the plant is scheduled to start production by 2027.
